News

People with amyotrophic lateral sclerosis (ALS) who received a high dose of the experimental therapy dazucorilant had a significantly higher chance of survival than patients given a lower dose or no treatment. That’s according to new analyses of data from the DAZALS Phase 2 clinical trial (NCT05407324), which…

May is ALS Awareness Month, and in the U.S. and around the world, organizations are educating, sponsoring events, and encouraging the community to join them in taking action, providing financial support, and pushing for better access to care through advocacy for those living with amyotrophic lateral sclerosis. The…

Vectory Therapeutics has been given a green light to expand its first-in-human clinical trial of VTx-002, its treatment candidate for amyotrophic lateral sclerosis (ALS), to sites in the U.K. and the European Union. The Phase 1/2 PIONEER-ALS study (NCT07287397) is already underway in the U.S., and is…

In France, the average family impacted by amyotrophic lateral sclerosis (ALS) has to pay thousands in out-of-pocket expenses to cover such things as mobility aids and paid caregivers — and because patients and caregivers often need to stop working to manage the disease, these expenses pile up on top…

RAG-17, an experimental treatment Ractigen Therapeutics is developing for people with amyotrophic lateral sclerosis (ALS) who carry a SOD1 mutation (SOD1-ALS), was well tolerated at multiple doses and led to profound changes in disease biomarkers, preliminary trial data showed. The data cover the first part of an ongoing…

Deaths from amyotrophic lateral sclerosis (ALS) have nearly doubled in Finland over the past three decades, with increases in mortality seen especially among older adults, according to a new study. The reasons for this trend aren’t clear, however, and the researchers noted that similar increases have not been reported…

The Muscular Dystrophy Association (MDA) will return to New York City on June 4 for its 26th annual Wings Over Wall Street Gala. Hosted at 48 Wall Street Events, the high-profile fundraiser unites the financial community and medical researchers to accelerate the search for a cure for amyotrophic…

Maintaining body weight after starting enteral nutrition, or tube feeding, may help extend survival in people with amyotrophic lateral sclerosis (ALS), a study in Japan suggests. In an analysis of 121 patients, those with smaller weight declines after starting tube feeding lived significantly longer, regardless of calorie intake at the…

Nearly half of the people with amyotrophic lateral sclerosis (ALS) treated with masitinib in a clinical trial survived for at least five years from disease onset — a marked improvement over historical data showing fewer than 1 in 4 ALS patients typically live this long — indicating what…

Long-term exposure to air pollution is not associated with an altered, or increased, risk of amyotrophic lateral sclerosis (ALS). That’s according to a new study from the U.K. that used data from more than 500,000 people in the European nation who were followed, on average, for nearly a decade.